Arizona is currently home to 1685 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Phoenix, Tucson, Scottsdale and Mesa. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
JAGUAR Trial: ObJective Analysis to GaUge EVAR Outcomes Through Randomization
NCT05064540
Recruiting
Prospective, randomized, multi-center study designed to evaluate the outcomes of commercially available contemporary EVAR in a real-world population. Patients will be randomized into two device cohorts and compared across the primary endpoints. Patients will be followed procedurally to discharge, at 1, 6, 12 months and annually through to 5 years (total follow-up commitment).
Gender:
ALL
Ages:
21 years and above
Trial Updated:
06/05/2025
Locations: University of Arizona, Tucson, Arizona
Conditions: AAA, AAA - Abdominal Aortic Aneurysm
Register for Updates
Adjuvant Treatment With Cisplatin-based Chemotherapy Plus Concomitant Atezolizumab in Patients With Stage I (Tumors ≥ 4cm), IIA, IIB, and Select Stage III [Any T1-3 N1-2 and T4N0-2] Resected Non-small Cell Lung Cancer (NSCLC) and the Clearance of Circulating Tumor DNA (ctDNA)
NCT04367311
Recruiting
The vast majority of patients with stage I (tumors ≥ 4cm), IIA, IIB (and select stage III) NSCLC are managed with upfront surgery, followed by adjuvant chemotherapy. However, relapse rates remain high and are primarily due to distant, metastatic disease. Previous meta-analysis evaluating the use of neo-adjuvant chemotherapy and adjuvant chemotherapy demonstrate a similar impact on improved disease free survival (DFS) and overall survival (OS). The role of checkpoint inhibitors has been proven to... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/05/2025
Locations: Banner MD Anderson Cancer Center, Gilbert, Arizona
Conditions: Lung Cancer, NSCLC
Register for Updates
HCRN Endoscopic Versus Shunt Treatment of Hydrocephalus in Infants
NCT04177914
Recruiting
Hydrocephalus is a potentially debilitating neurological condition that primarily affects babies under a year of age and has traditionally been treated by inserting a shunt between the brain and the abdomen. A newer endoscopic procedure offers hope of shunt- free treatment that may reduce complications over a child's life, but it is not clear if the endoscopic procedure results in similar intellectual outcome as shunt. Therefore, the investigators propose a randomized trial to compare intellectu... Read More
Gender:
ALL
Ages:
Between 1 day and 104 weeks
Trial Updated:
06/05/2025
Locations: Phoenix Children's Hospital, Phoenix, Arizona
Conditions: Hydrocephalus
Register for Updates
Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial
NCT03496883
Recruiting
The objective of the rFVIIa for Acute Hemorrhagic Stroke Administered at Earliest Time (FASTEST) Trial is to establish the first treatment for acute spontaneous intracerebral hemorrhage (ICH) within a time window and subgroup of patients that is most likely to benefit. The central hypothesis is that rFVIIa, administered within 120 minutes from stroke onset with an identified subgroup of patients most likely to benefit, will improve outcomes at 180 days as measured by the Modified Rankin Score (m... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
06/05/2025
Locations: St. Joseph's Hospital and Medical Center, Phoenix, Arizona
Conditions: Intracerebral Hemorrhage
Register for Updates
Early-Stage Partner in Care Living Alone Plus
NCT06962111
Recruiting
EPICLA+ (Early-Stage Partners in Care Living Alone Plus) is a research project designed to assist people with early-stage memory loss who live alone in the community by providing early-stage related education and skill-training sessions, held via Zoom, designed to reduce stress, enhance well-being, manage challenges, and plan for the future. Researchers will gather feedback from individuals about their experience to continue to improve programs for early-stage memory loss.
Gender:
ALL
Ages:
60 years and above
Trial Updated:
06/04/2025
Locations: Arizona State University, Phoenix, Arizona
Conditions: Dementia, Mild Cognitive Impairment (MCI), Alzheimer Disease
Register for Updates
A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)
NCT06782373
Recruiting
This study is to assess the effectiveness and safety of pacritinib in patients with VEXAS (i.e., Vacuoles in myeloid progenitors, E1 ubiquitin-activating enzyme, X-linked, autoinflammatory manifestations, and somatic) syndrome. 78 patients will be enrolled, randomized to either pacritinib dose A, pacritinib dose B + placebo, or placebo. Randomization will be stratified by prescribed GC dose on the day of randomization.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/04/2025
Locations: Mayo Clinic - Scottsdale, Scottsdale, Arizona
Conditions: VEXAS, VEXAS Syndrome
Register for Updates
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
NCT06682793
Recruiting
The goal of this study is to test A2B395, an allogeneic logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), triple-negative breast cancer (TNBC), renal cell carcinoma (RCC) and other solid tumors that express EGFR and have lost HLA-A\*02 expression. The main questions this study aims to answer are: * Phase 1: What is the recommended dose of A2B395 that is safe fo... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/04/2025
Locations: Banner MD Anderson Cancer Center, Gilbert, Arizona
Conditions: Solid Tumor, Adult, Colorectal Cancer, Non-Small Cell Lung, NSCLC (non-small Cell Lung Cancer), Cancer, Colon Cancer, Rectal Cancer, Lung Cancer, CRC, Head and Neck Squamous Cell Cancer, HNSCC, Renal Cell Carcinoma, RCC, Kidney Cancer, Triple Negative Breast Cancer, TNBC, Colorectal Adenocarcinoma
Register for Updates
A Trial to Test the Safety and Efficacy of TEV-53408 in Treating Vitiligo
NCT06625177
Recruiting
The primary objective of the trial is to evaluate the safety of TEV-53408 administered subcutaneously for the treatment of adults with vitiligo. A secondary objective is to further evaluate the safety of TEV-53408. The planned study period per participant is 84 weeks including a screening period (up to 4 weeks), a 24-week open-label treatment period, a 16-week washout period, and a 40-week follow-up period.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/04/2025
Locations: Teva Investigational Site 12043, Scottsdale, Arizona
Conditions: Vitiligo
Register for Updates
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
NCT06419374
Recruiting
The study will assess the efficacy and safety of pegozafermin administered in participants with compensated cirrhosis due to MASH (biopsy-confirmed fibrosis stage F4 MASH \[previously known as nonalcoholic steatohepatitis, NASH\]).
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/04/2025
Locations: 89bio Clinical Study Site, Chandler, Arizona
Conditions: Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
Register for Updates
Observational Study Protocol: LIVER-R
NCT06252753
Recruiting
Given the number of anticipated durvalumab-based treatment launches in the hepatobiliary cancer space over the next 3 years, there is a need to capture contemporary real-world data across these indications. LIVER-R is a multicountry, multicenter, observational study of patients with a confirmed diagnosis of hepatobiliary cancer treated with a durvalumab-based regimen as part of routine clinical practice or early access program (EAP). The study design will include primary and secondary data colle... Read More
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
06/04/2025
Locations: Research Site, Phoenix, Arizona
Conditions: Hepatobiliary Cancers
Register for Updates
A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)
NCT06223360
Recruiting
The purpose of this study is to learn more about the safety, effectiveness and tolerability of the study drug called Benfotiamine which may delay or slow the progression of the symptoms of early Alzheimer's disease.
Gender:
ALL
Ages:
Between 50 years and 89 years
Trial Updated:
06/04/2025
Locations: St. Joseph's Hospital and Medical Center/Barrow Neurological Institute, Phoenix, Arizona
Conditions: Alzheimer Disease
Register for Updates
TRIcvalve biCAVal Valve System for Severe Tricuspid Regurgitation (TRICAV-I)
NCT06137807
Recruiting
The TricValve® Transcatheter Bicaval Valve System is a bicaval transcatheter tricuspid valve replacement system, which includes the TricValve® Transcatheter Bicaval Valve for superior vena cava (SVC) and the TricValve® Transcatheter Bicaval Valve for inferior vena cava (IVC). The TricValve® Transcatheter Bicaval Valves are pre-mounted into the TricValve® Delivery System which is used for percutaneous access and delivery of the TricValve® Transcatheter Bicaval Valve in the vena cava. The system i... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/04/2025
Locations: St. Joseph's Hospital and Medical Center, Phoenix, Arizona
Conditions: Tricuspid Regurgitation, Tricuspid Valve Disease
Register for Updates